EUCTR2005-003707-37-AT进行中（未招募）不适用
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:
- •1) Males and females, 18 years of age or older.
- •2) Diagnosis of UC, as verified by endoscopy performed within 60 months prior to consent.
- •3) Severe active disease, as defined by MTWSI = 11 at consent, with a confirmatory MTWSI = 10 on or after the fifth consecutive day of IV steroids and within 1 day prior to randomization.
- •4) Mayo score = 10 and a Mayo mucosal subscore (finding of flexible proctosigmoidoscopy) of = 2. The Mayo score will be calculated on the day of sigmoidoscopy by a blinded gastroenterologist, after a minimum of 3 consecutive days (ie, on or after the fourth consecutive day) of IV steroids.
- •5) Agreement to use adequate contraception by male or female subjects of reproductive potential throughout the study and for 3 months after receiving the last dose of study drug.
- •6) Negative serum pregnancy test at screening in female subjects of childbearing potential.
- •7) Negative Clostridium difficile test within 10 days prior to the first dose of study drug.
- •8) Ability to understand the purpose and risks of the study and provide signed and dated informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria:
- •Subjects will be ineligible for this study if they meet any one of the following criteria:
- •1) UC requiring immediate surgical, endoscopic, or radiologic interventions, including massive hemorrhage, perforation and sepsis, suppurative complications (intra-abdominal or perianal abscesses), or toxic megacolon requiring imminent intervention.
- •2) History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis.
- •3) Presence of ileostomy.
- •4) White blood cell (WBC) count less than 2.5 x 10^3/mcL; platelet count less than 150 x 10^3/mcL; or hemoglobin (Hgb) level less than 8 g/dL. Note the following exceptions for WBC counts only (minimum platelet counts and Hgb levels are the same):
- •a) If subject has been taking the same dose of AZA/6-MP/MTX for 30 or more consecutive days immediately prior to consent, a WBC count <2.0 x 10^3/mcL.
- •b) If subject has initiated treatment with, or increased his/her dose of, 6-MP, AZA, or MTX within 30 days prior to consent, a WBC count of = 5 x 10^3/mcL at the time of screening.
- •5) Active medically significant infections, particularly those of viral etiology, eg, known CMV colitis. This includes any incidence of medically significant opportunistic infections (see Definitions) within the past 12 months.
- •6) Subjects may not receive a live vaccine within 6 weeks prior to randomization, during the visilizumab dosing period, or for 60 days after receiving the last dose of study drug.
- •7) Significant organ dysfunction, including cardiac, renal, liver, CNS, pulmonary, vascular, gastrointestinal, endocrine, or laboratory abnormality (eg, creatinine =1.6 mg/dL; ALT or AST = 2X the upper limit of normal [ULN]; alkaline phosphatase =1.5X ULN); a history of myocardial infarction, coronary artery disease, congestive heart failure, or arrhythmias within 6 months prior to consent.
- •8) History or treatment of lymphoproliferative disorder (LPD) or malignancy within the past 5 years (excluding nonmelanoma skin cancer or carcinoma in situ of the cervix).
- •9) Seropositive for infection with human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) surface antigen, or hepatitis C virus (HCV) antibody.
- •10) Treatment with a first dose of infliximab or another anti-TNF-a drug within 4 weeks of randomization, or treatment with a subsequent dose of an anti-TNF-a drug within 2 weeks of randomization.
- •11) Treatment with cyclosporine or tacrolimus (FK506) within 2 weeks prior to randomization.
- •12) Treatment with any other investigational drug or therapy within 60 days prior to randomization, except those mentioned in the above two exclusion criteria.
- •13) Any condition that, in the investigator’s opinion, makes the subject unsuitable for study participation.
- •14) Pregnancy or nursing.
- •15) Nontherapeutic levels of chronic anti-seizure medications in subjects with a prior history of seizures, as tested within 4 days prior to randomization.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone.MedDRA version: 18.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 Diabetes MellitusEUCTR2014-005153-39-BGexicon Pharmaceuticals, Inc.750
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s DiseaseModerately to severely active Crohn's diseaseMedDRA version: 18.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-022760-12-BEJanssen-Cilag International N.V.1,310
进行中（未招募）
1 期
Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic MigraineEpisodic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-002397-39-DEAmgen Inc.456
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy (RT/CT)Oral mucositisEUCTR2004-002016-28-ESAmgen Ltd315
进行中（未招募）
1 期
Chemoradiotherapy +/- pembrolizumab in participants with MIBCMuscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004023-20-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.636